http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112881692-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-067 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2021-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112881692-B |
| titleOfInvention | A protein quantitative detection method for early screening of colorectal cancer and adenoma |
| abstract | The invention discloses a protein quantitative detection method for early screening of colorectal cancer and adenoma. The present invention adopts the technology of label-free mass spectrometry to identify and quantify the large-scale proteome of colorectal cancer and its adenoma tissue, and screens out 32 protein markers, especially 3 proteins, namely TFR1, SAHH and HV307, in the Colorectal cancer and adenoma tissue and plasma were detected in different sample types, and there was a significant expression difference with the control group, and the AUC area of the ROC curve was up to 1. The performance of the protein marker screened by the invention is better than that of traditional protein tumor markers in the early screening of colorectal cancer and its precancerous lesion adenoma. The invention uses MRM mass spectrometry technology to identify and quantify target proteins in plasma samples, replacing traditional ELISA technology, independent of antibodies, and based on physical mass spectrometry signals, with high sensitivity, good reproducibility, high accuracy, and high throughput. |
| priorityDate | 2021-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 547.